Pharmaceutical Business review

Diamics cervical cancer test receives European approval

Comprised of the Pap-Map Cervical Cancer Collector, the Pap-Map Handle and the Transfer Station, the system allows the clinician to painlessly capture 360 degrees of cervical material and transfer the cells, with their spatial orientation intact, to a slide to support localization of identified lesions in both initial diagnosis and follow-up treatments.

Peter Gombrich, CEO of Diamics, said: “This CE Mark registration is a clear milestone for Diamics as it opens the door for commercialization of the system throughout the EU and other areas to help improve the detection of cervical cancer.”